Format

Send to

Choose Destination
AIDS Res Hum Retroviruses. 2012 Jan;28(1):1-15. doi: 10.1089/AID.2011.0053. Epub 2011 May 20.

How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Author information

1
Department of Microbiology and Immunology, Cornell University, Weill Cornell Medical College, New York, New York 10065-4896, USA. pek2003@med.cornell.edu

Abstract

No vaccine candidate has induced antibodies (Abs) that efficiently neutralize multiple primary isolates of HIV-1. Preexisting high titers of neutralizing antibodies (NAbs) are essential, because the virus establishes infection before anamnestic responses could take effect. HIV-1 infection elicits Abs against Env, Gag, and other viral proteins, but of these only a subset of the anti-Env Abs can neutralize the virus. Whereas the corresponding proteins from other viruses form the basis of successful vaccines, multiple large doses of HIV-1 Env elicit low, transient titers of Abs that are not protective in humans. The inaccessibility of neutralization epitopes hinders NAb induction, but Env may also subvert the immune response by interacting with receptors on T cells, B cells, monocytes, macrophages, and dendritic cells. Here, we discuss evidence from immunizations of different species with various modified Env constructs. We also suggest how the divergent Ab responses to Gag and Env during infection may reflect differences in B cell regulation. Drawing on these analyses, we outline strategies for improving Env as a component of a vaccine aimed at inducing strong and sustained NAb responses.

PMID:
21495876
PMCID:
PMC3251839
DOI:
10.1089/aid.2011.0053
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center